Kerrisdale Advisers LLC Purchases 48,678 Shares of Delcath Systems, Inc. (NASDAQ:DCTH)

Kerrisdale Advisers LLC lifted its position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 270.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 66,645 shares of the company's stock after purchasing an additional 48,678 shares during the period. Kerrisdale Advisers LLC owned about 0.21% of Delcath Systems worth $802,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp increased its holdings in Delcath Systems by 12.4% in the 3rd quarter. State Street Corp now owns 85,457 shares of the company's stock valued at $772,000 after acquiring an additional 9,400 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Delcath Systems in the third quarter worth about $110,000. Barclays PLC purchased a new stake in shares of Delcath Systems in the third quarter worth about $104,000. Geode Capital Management LLC lifted its position in shares of Delcath Systems by 3.0% in the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company's stock worth $2,275,000 after buying an additional 7,298 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Delcath Systems in the third quarter worth about $289,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Delcath Systems Stock Performance

DCTH stock traded up $0.20 during midday trading on Tuesday, reaching $12.20. 123,985 shares of the company traded hands, compared to its average volume of 355,534. Delcath Systems, Inc. has a 52-week low of $5.12 and a 52-week high of $16.97. The business has a 50 day moving average of $12.62 and a 200-day moving average of $12.45. The firm has a market capitalization of $407.88 million, a price-to-earnings ratio of -9.04 and a beta of 0.85.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The company had revenue of $15.10 million for the quarter, compared to analysts' expectations of $14.96 million. During the same quarter last year, the company earned ($0.48) earnings per share. Research analysts anticipate that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on DCTH shares. HC Wainwright boosted their target price on Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a research report on Friday, March 7th. Craig Hallum boosted their target price on Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a research report on Friday, January 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $22.75.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.